Latest Aeterna Zentaris (AEZS) Headlines
Stock to Watch: AEterna Zentaris Down 10.1% (AEZS)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing low-priced stocks, down 10.1% to $1.34 on 1.2x average daily volume. Thus far today, AEterna Zentaris has traded 1.3 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-10.1% to the Dow's -0.2%) and underperformed the S&P 500 (-10.1% to the S&P's -0.2%) during today's trading.
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
CNW Group - Wed Mar 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NASA Television Airs Departure of Commercial Cargo Ship from Space Station
Close-Up Media - Thu Feb 20, 12:18AM CST
NASA announced that Orbital Sciences' Cygnus cargo spacecraft, which delivered almost a ton-and-a-half of supplies and scientific experiments to the International Space Station in January, completes its month-long mission to the orbiting laboratory Tuesday, Feb. 18.
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
PR Newswire - Tue Feb 04, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article, "Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncology's ("ESGO") annual meeting in September 2011. The article is currently available at this link.
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
PR Newswire - Mon Feb 03, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
Windstream Receives 2013 ShoreTel Circle of Excellence Award
GlobeNewswire - Thu Jan 30, 12:04PM CST
Windstream (Nasdaq:WIN), a leading provider of advanced network communications, announced today that it has received ShoreTel's Circle of Excellence Award for the 2013 partner year. The award recognizes Windstream for exceptional achievement in areas including customer satisfaction, revenue growth and proficiency with advanced applications. ShoreTel, Inc. is the leading provider of brilliantly simple phone systems and unified communications solutions.
2013 North American Mobile Enterprise Applications
PR Newswire - Thu Jan 30, 6:10AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013 Report
M2 - Tue Jan 28, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/lvtfsj/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013" report to their offering. 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Scope - A snapshot of the global therapeutic scenario for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). - A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Amgen Inc. Sanofi Eli Lilly and Company Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Limited AEterna Zentaris Inc. Oncogenex Pharmaceuticals, Inc. Dendreon Corporation Debiopharm International S.A. Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/lv...ional_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Urticaria Or Hives - Pipeline Review, H2 2013
M2 - Fri Jan 24, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qwrdz/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H2 2013" report to their offering. 'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Urticaria Or Hives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives. Companies Mentioned - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - Sun Pharmaceutical Industries Limited - FAES Farma SA - AEterna Zentaris Inc. - JDP Therapeutics Inc. Scope - A snapshot of the global therapeutic scenario for Chronic Urticaria Or Hives. - A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Urticaria Or Hives pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. For more information visit http://www.researchandmarkets.com/research/4q..._urticaria
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Tue Jan 14, 10:15AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the closing of its previously announced public offering of 11.0 million units (the "Offering") generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.
Hot Stock: AEterna Zentaris, Shares Gain 5.0% (AEZS)
Comtex SmarTrend(R) - Fri Jan 10, 10:14AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 5.0% to $1.25 on 1.3x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (5.0% to the Dow's -0.2%) and outperformed the S&P 500 (5.0% to the S&P's -0.1%) during today's trading.
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Thu Jan 09, 7:31AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company") today announced the pricing of its previously announced public offering of 11.0 million units (the "Offering"), with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per share. Net proceeds from the Offering are expected to be approximately US$12.2 million, after deducting underwriting commissions and other expenses related to the Offering.
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
CNW Group - Wed Jan 08, 3:05PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company") today announced that it has commenced an underwritten public offering of units (the"Offering"), consisting of common shares and warrants to purchase common shares. The pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing.
Stock to Watch: AEterna Zentaris Down 10.1% (AEZS)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing low-priced stocks, down 10.1% to $1.34 on 1.2x average daily volume. Thus far today, AEterna Zentaris has traded 1.3 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-10.1% to the Dow's -0.2%) and underperformed the S&P 500 (-10.1% to the S&P's -0.2%) during today's trading.
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
CNW Group - Wed Mar 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NASA Television Airs Departure of Commercial Cargo Ship from Space Station
Close-Up Media - Thu Feb 20, 12:18AM CST
NASA announced that Orbital Sciences' Cygnus cargo spacecraft, which delivered almost a ton-and-a-half of supplies and scientific experiments to the International Space Station in January, completes its month-long mission to the orbiting laboratory Tuesday, Feb. 18.
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
PR Newswire - Tue Feb 04, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article, "Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncology's ("ESGO") annual meeting in September 2011. The article is currently available at this link.
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
PR Newswire - Mon Feb 03, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
Windstream Receives 2013 ShoreTel Circle of Excellence Award
GlobeNewswire - Thu Jan 30, 12:04PM CST
Windstream (Nasdaq:WIN), a leading provider of advanced network communications, announced today that it has received ShoreTel's Circle of Excellence Award for the 2013 partner year. The award recognizes Windstream for exceptional achievement in areas including customer satisfaction, revenue growth and proficiency with advanced applications. ShoreTel, Inc. is the leading provider of brilliantly simple phone systems and unified communications solutions.
2013 North American Mobile Enterprise Applications
PR Newswire - Thu Jan 30, 6:10AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013 Report
M2 - Tue Jan 28, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/lvtfsj/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013" report to their offering. 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Scope - A snapshot of the global therapeutic scenario for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). - A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Amgen Inc. Sanofi Eli Lilly and Company Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Limited AEterna Zentaris Inc. Oncogenex Pharmaceuticals, Inc. Dendreon Corporation Debiopharm International S.A. Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/lv...ional_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Urticaria Or Hives - Pipeline Review, H2 2013
M2 - Fri Jan 24, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qwrdz/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H2 2013" report to their offering. 'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Urticaria Or Hives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives. Companies Mentioned - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - Sun Pharmaceutical Industries Limited - FAES Farma SA - AEterna Zentaris Inc. - JDP Therapeutics Inc. Scope - A snapshot of the global therapeutic scenario for Chronic Urticaria Or Hives. - A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Urticaria Or Hives pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. For more information visit http://www.researchandmarkets.com/research/4q..._urticaria
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Tue Jan 14, 10:15AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the closing of its previously announced public offering of 11.0 million units (the "Offering") generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.
Hot Stock: AEterna Zentaris, Shares Gain 5.0% (AEZS)
Comtex SmarTrend(R) - Fri Jan 10, 10:14AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 5.0% to $1.25 on 1.3x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (5.0% to the Dow's -0.2%) and outperformed the S&P 500 (5.0% to the S&P's -0.1%) during today's trading.
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Thu Jan 09, 7:31AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company") today announced the pricing of its previously announced public offering of 11.0 million units (the "Offering"), with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per share. Net proceeds from the Offering are expected to be approximately US$12.2 million, after deducting underwriting commissions and other expenses related to the Offering.
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
CNW Group - Wed Jan 08, 3:05PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company") today announced that it has commenced an underwritten public offering of units (the"Offering"), consisting of common shares and warrants to purchase common shares. The pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing.
